Clinical Trial Results:
A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging phase II study to evaluate the pharmacodynamics, the safety and tolerability, and the pharmacokinetics of several intravenous regimens of the factor Xa inhibitor otamixaban (XRP0673), in comparison to intravenous unfractionated heparin, in subjects undergoing non-urgent Percutaneous Coronary Intervention.
Summary
|
|
EudraCT number |
2004-000904-41 |
Trial protocol |
SK ES CZ |
Global completion date |
19 Oct 2005
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Jun 2016
|
First version publication date |
04 Jun 2016
|
Other versions |
|
Summary report(s) |
DRI6199 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.